A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Clinical trial NCT06312137 · RECRUITING
Trial details
- NCT number
- NCT06312137
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-03
- Primary completion
- 2034-02-21
- Enrollment
- 780
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.